| Literature DB >> 30352491 |
Do-Hyoung Kim1, Kyou-Hoon Han1.
Abstract
Intrinsically disordered proteins (IDPs) are highly unorthodox proteins that do not form three-dimensional structures under physiological conditions. The discovery of IDPs has destroyed the classical structure-function paradigm in protein science, 3-D structure = function, because IDPs even without well-folded 3-D structures are still capable of performing important biological functions and furthermore are associated with fatal diseases such as cancers, neurodegenerative diseases and viral pandemics. Pre-structured motifs (PreSMos) refer to transient local secondary structural elements present in the target-unbound state of IDPs. During the last two decades PreSMos have been steadily acknowledged as the critical determinants for target binding in dozens of IDPs. To date, the PreSMo concept provides the most convincing structural rationale explaining the IDP-target binding behavior at an atomic resolution. Here we present a brief developmental history of PreSMos and describe their common characteristics. We also provide a list of newly discovered PreSMos along with their functional relevance.Entities:
Keywords: IDPs; IDR (Intrinsically Disordered Region); IUPs (Intrinsically Unfolded Proteins); NMR; PreSMos (Pre-Structured Motifs)
Mesh:
Substances:
Year: 2018 PMID: 30352491 PMCID: PMC6199570 DOI: 10.14348/molcells.2018.0192
Source DB: PubMed Journal: Mol Cells ISSN: 1016-8478 Impact factor: 5.034
A list of MU-type IDPs/IDRs containing PreSMos
| Name | Number of residues | P/R | Location of PreSMo residues | Population | Role/Binding | References |
|---|---|---|---|---|---|---|
| FlgM | 97 | P | 60–73 | 50±10 | σ28 | |
| 83–90 | 50±10 | |||||
| 42–50 | 20 | |||||
| KID | 60 | R | 119–129 | >50 | KIX | |
| 134–143 | ~10 | |||||
| GBD/CRIB in WASP W7 | 68 | R | 252–264 | ~14 | Cdc42/Rac | |
| (201–268) | ||||||
| HIV-1 Nef | 56 | R | 14–22 : helix I | 18 | ||
| (2–57) | 35–41 : helix II (Hα only) | |||||
| Synaptobrevin-2 | 96 | R | 78–91 | 45 | core complex forming | |
| APPC | 47 | R | 20–23 | 30 | X11 | |
| (649–695) | 27–35 | 20 | ||||
| 37–45 (Hα only) | 30 | |||||
| p53 TAD | 73 | R | 18–26 : helix | 20 | Mdm2 | |
| 40–44 : turn I | 5 | RPA, TFEII | ||||
| 48–53 : turn II | 15 | |||||
| RPS4 | 200 | P | 12–15 | 8 | rRNA, ribosomal proteins | |
| 30–33: β? | 23 | |||||
| α-Synuclein | 140 | P | 18–31 | ~10 | amyloid-forming | |
| N-term. Tmod 1 | 92 | R | 24–35 | NA | tropomyosin | |
| VP16 TAD | 79 | 443–447 | 25 | hTAFII31 PC4 | ||
| (412–490) | R | 469–483 | 15 | |||
| VP16 TAD | 79 | R | 424–433/442–446, 465–467/472–479 (Hα only) | 60/40 | hTAFII31 PC4 | |
| (412–490) | 10/20 | |||||
| Dynein interm. chain | 40 | R | 223–228 | NA | light chains | |
| (198–237) | ||||||
| γ-Synuclein | 127 | P | 49–99 | ~15 | ||
| HMGA1 | 107 | P | 3–9 | 8 | 20 different proteins | |
| 64–67 | ||||||
| CFTR | 185 | R | interaction between R region and NT-binding domain 1 | |||
| (654–838) | 654–668, 759–764, 766–776, 801–817 | >5 | ||||
| >5 | ||||||
| 744–753 | >5 | |||||
| NS5A-D2 (HCV) | 93 | R | L48-V57 | 20 | - | |
| (250–342) | L86-E96 (Hα only) | 25 | ||||
| preS1 of HBV | 119 | R | 32–36, 41–45 | ~10 | hepatocyte receptor-binding | |
| 11–18, 22–25, 37–40, 46–50. (Hα only) | ~10 | |||||
| ~10 | ||||||
| β-synuclein | 134 | P | NA | ~20 | - | |
| Securin | 202 | P | 150–159 : helix | 45 | - | |
| 113–127 (β) | 15 | |||||
| 174–178 | 20 | |||||
| C-XPC | 126 | R | 818–843: helix | ~30 | Centri2 | |
| (815–940) | 847–860: helix | ~30 | TFIIH | |||
| 891–901: helix | NA | |||||
| 908–915: helix | NA | |||||
| 923–930: helix | NA | |||||
| MSP2 | 237 | P | 14–21 | 35 | - | |
| 140–150 | 35 | |||||
| 197–211 | 20 | |||||
| DARPP-32 | 118 | R | 22–29 | 50 | PP1 | |
| 103–114 | 25 | |||||
| I-2 | 156 | R | 36–42 | 30 | PP1 | |
| (9–164) | 96–106 | 48 (70) | ||||
| 127–154 | 67 (90) | |||||
| 132–138 | >98 | |||||
| ENSA | 121 | P | 32–36 | 40 | - | |
| 48–50 | 10 | |||||
| 65–70 | 30 | |||||
| ODD/HIF-1α | 74 | R | 438–440 | ~10 | - | |
| (404–477) | 467–477 | |||||
| Sml1 | 104 | P | 4–14: helix | ~20 | RNR binding | |
| (1–104) | 61–80: helix | ~70 | Dimer forming | |||
| Myb25 | 25 | R | 295–309 : helix | 25~30 | KIX | |
| (291–315) | ||||||
| N tail | 125 | R | 488–499 : helix | NA | phosphoprotein P | |
| Measles virus nucleoprotein | (401–525) | |||||
| dSLBP | 92 | R | 28–45 : helix | NA | mRNA | |
| (17–108) | 50–57 : helix | stem-loop | ||||
| 66–75 : helix | ||||||
| 91–96 : helix | ||||||
| Tβ-4 | 43 | P | 5–16 : helix | NA | Ca ATP | |
| (1–43) | G-actin | |||||
| N tail | 82 | R | 479–484 | 36 | phosphoprotein P | |
| Sendai Virus nucleoprotein | (443–524) | 476–488 | 38 | |||
| 478–492 | 11 | |||||
| Sic1 | 90 | R | 20–30 | 20 | Cdc4 | |
| (1–90) | 63–68 | |||||
| c-Myc | 88 | R | 26–34 : helix | 40 | Bin-SH3 domain | |
| (1–88) | 47–52 : helix | 25 | 24–31(TRRAP binding) | |||
| 20–23 : β-turn | ||||||
| ExsE | 88 | P | 42–51: helix | NA | ExsC | |
| (1–88) | 61–65: helix | |||||
| NS5A | 415 | R | 401–412 : helix | NA | Bin1-SH3 | |
| HCV | (33–447) | 427–445 : helix | ||||
| NS5A | 179 | R | 205–221 : helix I | 38 | Bin1-SH3 | |
| HCV | (191–369) | 251–266 : helix II | 38 | |||
| 292–306 : helix III | 51 | |||||
| 4EBP2 | 120 | P | 1–5 | 15~37 | eIF4E | |
| (1–120) | 33–37 | |||||
| 50–64 | ||||||
| 86–89 | ||||||
| 96–105 | ||||||
| E7 | 40 | R | 8–13 : helix | NA | E2 | |
| HPV | (1–40) | 17–29 : helix | ||||
| 33–38 : PPII | ||||||
| 4EBP1 | 70 | R | 56–63 : helix | 20 | eIF4E | |
| (49–118) | ||||||
| Myb32 | 32 | R | 290–310 : helix | ~70 | KIX | |
| (284–315) | ||||||
| E7 | 46 | R | 7–14 : helix | 10 | E2 | |
| HPV | (1–46) | 20–26 : helix | 20 | |||
| CBP-ID4 | 207 | R | 1852–1875: helix | ~60 | - | |
| (1851–2057) | 1951–1978: helix | |||||
| HIV-1 Tat | 121 | P | 27–32: helix | ~20 | Fab’ | |
| (1–121) | 41–59: helix | ~30 | P-TEFb | |||
| 70–81: β sheet | ~25 | TAR-cyclin T1 | ||||
| 93–99: β sheet | ~25 | |||||
| 105–112: β sheet | ~10 | |||||
| SUSP4 | 100 | R | 263–291 : helix | ~30 | mdm2 | |
| (201–300) | 265–270 : helix | ~10 | ||||
| 281–291 : helix | ||||||
| hGRtau1c | 64 | R | 185–202: helix | 20~30 | TAZ2 | |
| (181–244) | 206–225: helix | |||||
| 232–244: helix | ||||||
| Huntingtin Httex1 25Q | 95 | P | 18–42: helix | NA | Cytotoxic | |
| (1–95) | Membrane binding | |||||
| Aggregation |
The numbering includes a 20-residue N-terminal tag.
An IDP (P) versus an IDR (R).
Residue numbers are taken from the original report.
Population of PreSMos are read from the mid-point of the SSP scores that are calculated from chemical shifts in BMRB or literature. Shown in bold are the populations described in the original report. When the populations described in the original report without SSP scores differed significantly from the calculated SSP scores, the SSP scores are provided in parenthesis.
NA = not available.
Determined by SAXS.
Fig. 1PreSMo vs. MoRF. A schematic diagram of the main differences between a PreSMo and a MoRF
A PreSMo is observed mostly by NMR experiments in the target-free state of IDPs. Since free-state IDPs exist as an ensemble of many conformers separated by small energy differences, structural superposition among different conformers along the backbone atoms is not possible. Nevertheless, a structural zsuperposition along a PreSMo is possible as shown in the left panel for the helix PreSMo of 4EBP1 (Kim et al., 2015). A PreSMo may become a MoRF upon target binding as illustrated for this helix PreSMo in 4EBP1 which becomes an α-MoRF when bound to eIF4E.